Larimar Therapeutics to Present at the Oppenheimer Fall Healthcare Life Sciences & MedTech Summit
Larimar Therapeutics (Nasdaq: LRMR), a clinical-stage biotechnology company, announced that CEO Carole Ben-Maimon will present virtually at the Oppenheimer Fall Healthcare Life Sciences & MedTech Summit on September 21, 2020, at 1:40 p.m. EDT. The company focuses on developing treatments for complex rare diseases, with its lead compound CTI-1601 currently in Phase 1 clinical trials aimed at addressing Friedreich’s ataxia. Larimar intends to utilize its intracellular delivery platform to create additional fusion proteins targeting other rare diseases.
- None.
- None.
BALA CYNWYD, Pa., Sept. 21, 2020 (GLOBE NEWSWIRE) -- Larimar Therapeutics, Inc. (Nasdaq:LRMR), a clinical-stage biotechnology company focused on developing treatments for complex rare diseases, today announced that Carole Ben-Maimon, MD, President and Chief Executive Officer, will virtually present at the Oppenheimer Fall Healthcare Life Sciences & MedTech Summit on Monday, September 21, 2020, at 1:40 p.m. EDT.
About Larimar Therapeutics
Larimar Therapeutics, Inc. (Nasdaq:LRMR), is a clinical-stage biotechnology company focused on developing treatments for complex rare diseases. The company’s lead compound, CTI-1601, is currently being evaluated in a Phase 1 clinical program in the U.S. as a potential treatment for Friedreich’s ataxia, a rare and progressive genetic disease. Larimar also plans to use its intracellular delivery platform to design other fusion proteins to target additional rare diseases characterized by deficiencies in intracellular bioactive compounds. For more information, please visit: https://larimartx.com.
Investor Contact:
Mike Celano
Larimar Therapeutics
(215) 327-1838
mcelano@larimartx.com
Media Contact:
Gina Cestari
6 Degrees
(917) 797-7904
gcestari@6degreespr.com
FAQ
What announcement did Larimar Therapeutics make on September 21, 2020?
What is the focus of Larimar Therapeutics?
What is the lead compound of Larimar Therapeutics?
What is Friedreich’s ataxia?
What date is the Oppenheimer Fall Healthcare Life Sciences & MedTech Summit?
